Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 3800 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 2850 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 1900 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: water for injections - compound sodium lactate solution and 5% glucose is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are compatible with the solutions.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - solution - excipient ingredients: meglumine; water for injections; tetraxetan - clariscan is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - solution - excipient ingredients: meglumine; water for injections; tetraxetan - clariscan is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - solution - excipient ingredients: meglumine; water for injections; tetraxetan - clariscan is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

i-care pharma distributors pty ltd - ocriplasmin, quantity: 1.25 mg/ml - injection, solution - excipient ingredients: mannitol; citric acid monohydrate; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - jetrea rtu is indicated in adults for the treatment of vitreomacular traction (vmt), including when associated with macular hole of diameter less than or equal to 400 microns.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - solution - excipient ingredients: meglumine; water for injections; tetraxetan - clariscan is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - solution - excipient ingredients: meglumine; water for injections; tetraxetan - clariscan is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).